IGFBP2 and metabolic dysfunction-associated steatotic liver disease: Since the reverse, increased methylation and decreased expression of IGFBP2, is found in both mice and humans with NAFLD and NASH (Ahrens et al., 2013), this CR-mediated change in Igfbp2 levels indicates metabolic improvements (Nam et al., 1997; Heald et al., 2006; Carter et al., 2014).